The molecular pathogenesis and management of bronchial carcinoids

Bibliography

• Eriksson B, Oberg K. Carcinoid syndrome. In: Jameson JL, De Groot LJ, editors, Endocrinology. Saunders Elsevier, Philadelphia, PA; 2010. p. 2774-86
   Google Scholar
• Leotlela PD, Jauch A, Holtgreve-Grez H, Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003;10:437-50
   PubMed Web of Science ®Google Scholar
• Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002;14:38-45
   PubMedGoogle Scholar
• Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer 2009;45(Suppl 1):251-66
   PubMedGoogle Scholar
• Travis WD, Colby TV, Corrin B, The spectrum of neuroendocrine tumours. In: Sobin LH, editor, WHO International histological classification of tumours. Histological typing of lung and pleural tumours. Springer-Verlag, Berlin; 1999. p. 7-9
   Google Scholar
• Phan AT, Oberg K, Choi J, NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010;39:784-98
   PubMed Web of Science ®Google Scholar
• Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. Hematol Oncol Clin North Am 2007;21:395-407
   PubMedGoogle Scholar
• Bertino EM, Confer PD, Colonna JE, Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 2009;115:4434-41
   PubMedGoogle Scholar
• Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC, Lyon; 2004
   Google Scholar
• Siddiqui MT. Pulmonary neuroendocrine neoplasms: a review of clinicopathologic and cytologic features. Diagn Cytopathol 2010;38:607-17
   PubMedGoogle Scholar
• Gustafsson BI, Kidd M, Chan A, Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5-21
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59
   PubMed Web of Science ®Google Scholar
• Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367-75
   PubMed Web of Science ®Google Scholar
• Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005;103:509-15
   PubMedGoogle Scholar
• Demay RM. Lung. In: Demay RM, editor, The art and science of cytopathology. American Society of Clinical Pathologists Press, Chicago, IL; 1996. p. 947-98
   Google Scholar
• Davies SJ, Gosney JR, Hansell DM, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognized spectrum of disease. Thorax 2007;62:248-52
   PubMedGoogle Scholar
• Skov BG, Krasnik M, Lantuejoul S, Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 2008;3:1410-15
   PubMedGoogle Scholar
• Fathi Z, Corjay MH, Shapira H, BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993;268:5979-84
   PubMed Web of Science ®Google Scholar
• Moody TW, Zia F, Venugopal R, GRP receptors are present in non small cell lung cancer cells. J Cell Biochem Suppl 1996;24:247-56
   PubMedGoogle Scholar
• Ryan RR, Weber HC, Mantey SA, Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells. J Pharmacol Exp Ther 1998;287:366-80
   PubMed Web of Science ®Google Scholar
• Lai SL, Perng RP, Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 2000;7:64-70
   PubMed Web of Science ®Google Scholar
• Kazanjian A, Wallis D, Au N, Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. Cancer Res 2004;64:6874-82
   PubMed Web of Science ®Google Scholar
• Kunnimalaiyaan M, Yan S, Wong F, Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery 2005;138:1137-42
   PubMed Web of Science ®Google Scholar
• Plummer HK III, Dhar M, Schuller HM. Expression of the alpha7 nicotinic acetylcholine receptor in human lung cells. Respir Res 2005;6:29
   PubMed Web of Science ®Google Scholar
• Plummer HK III, Dhar MS, Cekanova M, Expression of G-protein inwardly rectifying potassium channels (GIRKs) in lung cancer cell lines. BMC Cancer 2005;5:104
   PubMed Web of Science ®Google Scholar
• Ahmed AU, Schmidt RL, Park CH, Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst 2008;100:1606-29
   PubMedGoogle Scholar
• Castano Z, Vergara-Irigaray N, Pajares MJ, Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. Int J Cancer 2008;122:1512-20
   PubMedGoogle Scholar
• Pitt SC, Chen H, Kunnimalaiyaan M. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg 2009;209:82-8
   PubMedGoogle Scholar
• Stepien T, Sacewicz M, Lawnicka H, Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. Neuropeptides 2009;43:397-400
   PubMedGoogle Scholar
• Cortes-Sempere M, Chattopadhyay S, Rovira A, MKP1 repression is required for the chemosensitizing effects of NFkappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett 2009;286:206-16
   PubMedGoogle Scholar
• Rickman OB, Vohra PK, Sanyal B, Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res 2009;15:3315-24
   PubMedGoogle Scholar
• Gilbert JA, Adhikari LJ, Lloyd RV, Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010;17:623-36
   PubMedGoogle Scholar
• Haley SA, O'Hara BA, Banerjee R, Unique susceptibility of a human lung carcinoid tumor cell line to infection with BK virus. Virus Res 2010;149:128-32
   PubMedGoogle Scholar
• Svejda B, Kidd M, Giovinazzo F, The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer 2010;116:2902-12
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Caplin ME, Waugh MG, Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics 2010;9:656-66
   PubMedGoogle Scholar
• Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 2007;12:535-42
   PubMed Web of Science ®Google Scholar
• Jakobovitz O, Nass D, DeMarco L, Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab 1996;81:3164-7
   PubMedGoogle Scholar
• Debelenko LV, Brambilla E, Agarwal SK, Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285-90
   PubMed Web of Science ®Google Scholar
• Onuki N, Wistuba II, Travis WD, Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999;85:600-7
   PubMed Web of Science ®Google Scholar
• Finkelstein SD, Hasegawa T, Colby T, 11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice. Am J Pathol 1999;155:633-40
   PubMedGoogle Scholar
• Vageli D, Daniil Z, Dahabreh J, Microsatellite instability and loss of heterozygosity at the MEN1 locus in lung carcinoid tumors: a novel approach using real-time PCR with melting curve analysis in histopathologic material. Oncol Rep 2006;15:557-64
   PubMedGoogle Scholar
• Petzmann S, Ullmann R, Klemen H, Loss of heterozygosity on chromosome arm 11q in lung carcinoids. Hum Pathol 2001;32:333-8
   PubMedGoogle Scholar
• Gortz B, Roth J, Krahenmann A, Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999;154:429-36
   PubMedGoogle Scholar
• Hurr K, Kemp B, Silver SA, Microsatellite alteration at chromosome 3p loci in neuroendocrine and non-neuroendocrine lung tumors. Histogenetic and clinical relevance. Am J Pathol 1996;149:613-20
   PubMedGoogle Scholar
• Kovatich A, Friedland DM, Druck T, Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors. Cancer 1998;83:1109-17
   PubMed Web of Science ®Google Scholar
• Sugio K, Osaki T, Oyama T, Genetic alteration in carcinoid tumors of the lung. Ann Thorac Cardiovasc Surg 2003;9:149-54
   PubMedGoogle Scholar
• Kobayashi Y, Tokuchi Y, Hashimoto T, Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci 2004;95:334-41
   PubMed Web of Science ®Google Scholar
• Pearce SH, Trump D, Wooding C, Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 1996;45:195-200
   PubMed Web of Science ®Google Scholar
• D'Adda T, Bottarelli L, Azzoni C, Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors. Mod Pathol 2005;18:795-805
   PubMedGoogle Scholar
• D'Alessandro V, Muscarella LA, la Torre A, Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer 2010;67:69-75
   Google Scholar
• Walch AK, Zitzelsberger HF, Aubele MM, Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol 1998;153:1089-98
   PubMedGoogle Scholar
• Ullmann R, Petzmann S, Klemen H, The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues. Genes Chromosomes Cancer 2002;34:78-85
   PubMedGoogle Scholar
• Zhao J, de Krijger RR, Meier D, Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol 2000;157:1431-38
   PubMed Web of Science ®Google Scholar
• Petzmann S, Ullmann R, Halbwedl I, Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study. Virchows Arch 2004;445:151-9
   PubMedGoogle Scholar
• Warth A, Herpel E, Krysa S, Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Exp Mol Med 2009;41:349-53
   PubMed Web of Science ®Google Scholar
• Voortman J, Lee JH, Killian JK, Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 2010;107:13040-5
   PubMed Web of Science ®Google Scholar
• Couce ME, Bautista D, Costa J, Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms. Diagn Mol Pathol 1999;8:71-9
   PubMedGoogle Scholar
• Lohmann DR, Fesseler B, Putz B, Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993;53:5797-801
   PubMedGoogle Scholar
• Przygodzki RM, Finkelstein SD, Langer JC, Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996;148:1531-41
   PubMedGoogle Scholar
• Perren A, Schmid S, Locher T, BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004;11:855-60
   PubMedGoogle Scholar
• Dong Q, Debelenko LV, Chandrasekharappa SC, Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1997;82:1416-20
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Tazelaar HD, Wentzlaff KA, Familial pulmonary carcinoid tumors. Cancer 2001;91:2104-9
   PubMedGoogle Scholar
• Toyooka S, Toyooka KO, Maruyama R, DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-7
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Toyooka S, Eby MT, Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002;1:65-169
   PubMed Web of Science ®Google Scholar
• Sathyanarayana UG, Toyooka S, Padar A, Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin Cancer Res 2003;9:2665-7
   PubMedGoogle Scholar
• Momparler RL, Eliopoulos N, Ayoub J. Evaluation of an inhibitor of DNA methylation, 5-aza-2o´-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy. Adv Exp Med Biol 2000;465:433-46
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J, Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-5
   PubMed Web of Science ®Google Scholar
• He P, Varticovski L, Bowman ED, Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol 2004;35:1196-209
   PubMedGoogle Scholar
• Kim do H, Nagano Y, Choi IS, Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 2008;47:84-92
   PubMedGoogle Scholar
• Morandi U, Casali C, Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg 2006;18:191-8
   PubMedGoogle Scholar
• Reubi JC, Kappeler A, Waser B, Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 1998;153:233-45
   PubMed Web of Science ®Google Scholar
• Papotti M, Croce S, Macri L, Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47-57
   PubMedGoogle Scholar
• Papotti M, Croce S, Bello M, Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001;439:787-97
   PubMed Web of Science ®Google Scholar
• Righi L, Volante M, Tavaglione V, Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol 2010;21:548-55
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW, Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007;92:65-9
   PubMed Web of Science ®Google Scholar
• Grossrubatscher E, Veronese S, Ciaramella PD, High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biol Ther 2008;7:1970-8
   PubMed Web of Science ®Google Scholar
• Sica G, Wagner PL, Altorki N, Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med 2008;132:1889-95
   PubMedGoogle Scholar
• Brambilla E, Constantin B, Drabkin H, Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 2000;156:939-50
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Constantin B, Drabkin H, Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003;200:336-47
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Hasleton PS, Wilkes S, Lack of C-erbB-2 protein expression in pulmonary carcinoid tumours. J Clin Pathol 1991;44:343
   PubMedGoogle Scholar
• Granberg D, Wilander E, Oberg K. Expression of tyrosine kinase receptors in lung carcinoids. Tumour Biol 2006;27:153-7
   PubMed Web of Science ®Google Scholar
• Roncalli M, Doglioni C, Springall DR, Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications. Diagn Mol Pathol 1992;1:129-35
   PubMedGoogle Scholar
• Barbareschi M, Girlando S, Mauri FA, Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol 1992;166:343-50
   PubMedGoogle Scholar
• Wang BY, Gil J, Kaufman D, P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 2002;33:921-6
   PubMed Web of Science ®Google Scholar
• Au NH, Gown AM, Cheang M, P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004;12:240-7
   PubMedGoogle Scholar
• Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798-809
   PubMedGoogle Scholar
• Brambilla E, Negoescu A, Gazzeri S, Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52
   PubMed Web of Science ®Google Scholar
• Coppola D, Clarke M, Landreneau R, Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Mod Pathol 1996;9:484-90
   PubMedGoogle Scholar
• Wang DG, Johnston CF, Sloan JM, Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53. J Pathol 1998;184:247-51
   PubMedGoogle Scholar
• Zirbes TK, Lorenzen J, Baldus SE, Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Histopathology 1998;33:123-8
   PubMedGoogle Scholar
• Laitinen KL, Soini Y, Mattila J, Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer 2000;88:1590-8
   PubMedGoogle Scholar
• LaPoint RJ, Bourne PA, Wang HL, Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. Appl Immunohistochem Mol Morphol 2007;15:401-6
   PubMedGoogle Scholar
• Cagle PT, el-Naggar AK, Xu HJ, Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol 1997;150:393-400
   PubMed Web of Science ®Google Scholar
• Gouyer V, Gazzeri S, Bolon I, Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998;18:188-96
   PubMed Web of Science ®Google Scholar
• Dosaka-Akita H, Cagle PT, Hiroumi H, Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. Cancer 2000;88:550-6
   PubMed Web of Science ®Google Scholar
• Beasley MB, Lantuejoul S, Abbondanzo S, The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34:136-42
   PubMed Web of Science ®Google Scholar
• Igarashi T, Jiang SX, Kameya T, Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004;17:1259-67
   PubMed Web of Science ®Google Scholar
• Sarvesvaran J, Going JJ, Milroy R, Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999;20:1649-51
   PubMedGoogle Scholar
• Zaffaroni N, De Polo D, Villa R, Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol 2003;201:127-33
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, Villa R, Pastorino U, Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres. Clin Cancer Res 2005;11:2832-9
   PubMed Web of Science ®Google Scholar
• Nishio Y, Nakanishi K, Ozeki Y, Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors. Jpn J Clin Oncol 2007;37:16-22
   PubMedGoogle Scholar
• Clavel CE, Nollet F, Berx G, Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours. J Pathol 2001;194:20-6
   PubMedGoogle Scholar
• Salon C, Moro D, Lantuejoul S, E-cadherin-beta-catenin adhesion complex in neuroendocrine tumors of the lung: a suggested role upon local invasion and metastasis. Hum Pathol 2004;35:1148-55
   PubMedGoogle Scholar
• Pelosi G, Scarpa A, Puppa G, Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer 2005;103:1154-64
   PubMedGoogle Scholar
• Galvan JA, Gonzalez MV, Crespo G, Snail nuclear expression parallels higher malignancy potential in neuroendocrine lung tumors. Lung Cancer 2010;69:289-95
   PubMedGoogle Scholar
• Pelosi G, Pasini F, Fraggetta F, Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003;42:203-13
   PubMed Web of Science ®Google Scholar
• Fabbro D, Di Loreto C, Stamerra O, TTF-1 gene expression in human lung tumours. Eur J Cancer 1996;32A:512-17
   PubMed Web of Science ®Google Scholar
• Folpe AL, Gown AM, Lamps LW, Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999;12:5-8
   PubMed Web of Science ®Google Scholar
• Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000;36:415-20
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Tazelaar HD, Myers JL, Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-19
   PubMedGoogle Scholar
• Sturm N, Rossi G, Lantuejoul S, Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33:175-82
   PubMedGoogle Scholar
• Du EZ, Goldstraw P, Zacharias J, TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol 2004;35:825-31
   PubMed Web of Science ®Google Scholar
• Saqi A, Alexis D, Remotti F, Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005;123:394-404
   PubMed Web of Science ®Google Scholar
• Lin X, Saad RS, Luckasevic TM, Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007;15:407-14
   PubMedGoogle Scholar
• Moskaluk CA, Zhang H, Powell SM, Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-19
   PubMedGoogle Scholar
• Jaffee IM, Rahmani M, Singhal MG, Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med 2006;130:1522-6
   PubMed Web of Science ®Google Scholar
• Matoso A, Singh K, Jacob R, Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 2010;18:142-9
   PubMedGoogle Scholar
• Khoor A, Stahlman MT, Johnson JM, Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors. Hum Pathol 2004;35:560-4
   PubMedGoogle Scholar
• Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-72
   PubMed Web of Science ®Google Scholar
• Cai YC, Banner B, Glickman J, Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2001;32:1087-93
   PubMedGoogle Scholar
• Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009;33:626-32
   PubMed Web of Science ®Google Scholar
• Salon C, Merdzhanova G, Brambilla C, E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007;26:6927-36
   PubMed Web of Science ®Google Scholar
• Salon C, Brambilla E, Brambilla C, Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 2007;213:303-10
   PubMed Web of Science ®Google Scholar
• Jiang SX, Kameya T, Asamura H, hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004;17:222-9
   PubMed Web of Science ®Google Scholar
• Granberg D, Skogseid B, Welin S, Gastrin-releasing-peptide in neuroendorine tumours. Acta Oncol 2006;45:23-7
   PubMed Web of Science ®Google Scholar
• Wang LJ, Greaves WO, Sabo E, GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol 2009;17:505-11
   PubMedGoogle Scholar
• Senden NH, Timmer ED, de Bruine A, A comparison of NSP-reticulons with conventional neuroendocrine markers in immunophenotyping of lung cancers. J Pathol 1997;182:13-21
   PubMed Web of Science ®Google Scholar
• Arbiser ZK, Arbiser JL, Cohen C, Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol 2001;14:1195-9
   PubMedGoogle Scholar
• Katsetos CD, Kontogeorgos G, Geddes JF, Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000;124:535-44
   PubMed Web of Science ®Google Scholar
• Liu Y, Sturgis CD, Grzybicki DM, Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma. Mod Pathol 2001;14:880-5
   PubMedGoogle Scholar
• Sturm N, Rossi G, Lantuejoul S, 34betaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology 2003;42:156-66
   PubMed Web of Science ®Google Scholar
• Ricci A, Graziano P, Mariotta S, Neurotrophin system expression in human pulmonary carcinoid tumors. Growth Factors 2005;23:303-12
   PubMed Web of Science ®Google Scholar
• Cooper CS, Nicholson AG, Foster C, Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer 2006;54:155-62
   PubMedGoogle Scholar
• Johnson KR, Johnson KY, Crellin HG, Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 2005;53:1159-66
   PubMed Web of Science ®Google Scholar
• Lai M, Lu B, Xing X, Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A. Virchows Arch 2006;449:402-9
   PubMedGoogle Scholar
• Rumilla KM, Erickson LA, Erickson AK, Galectin-4 expression in carcinoid tumors. Endocr Pathol 2006;17:243-9
   PubMedGoogle Scholar
• Pelosi G, Leon ME, Veronesi G, Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors. J Thorac Oncol 2006;1:468-77
   PubMedGoogle Scholar
• Xu H, Bourne PA, Spaulding BO, High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007;38:555-63
   PubMedGoogle Scholar
• Shilo K, Dracheva T, Mani H, Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. Arch Pathol Lab Med 2007;131:1555-60
   PubMedGoogle Scholar
• Moldvay J, Jackel M, Paska C, Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 2007;57:159-67
   PubMedGoogle Scholar
• Kasprzak A, Olejniczak K, Przybyszewska W, Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz) 2007;66:159-66
   PubMedGoogle Scholar
• Kaira K, Oriuchi N, Imai H, Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008;204:553-61
   PubMedGoogle Scholar
• Amin RM, Hiroshima K, Iyoda A, LKB1 protein expression in neuroendocrine tumors of the lung. Pathol Int 2008;58:84-8
   PubMedGoogle Scholar
• Ceppi P, Volante M, Ferrero A, Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008;14:1059-64
   PubMed Web of Science ®Google Scholar
• Kim HS, Yi SY, Jun HJ, L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS 2009;117:140-6
   PubMedGoogle Scholar
• Ozbudak IH, Shilo K, Tavora F, Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol 2009;22:633-8
   Google Scholar
• Shimakage M, Kodama K, Kawahara K, Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors. Oncol Rep 2009;21:1367-72
   PubMedGoogle Scholar
• Kanteti R, Nallasura V, Loganathan S, PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009;89:301-14
   PubMedGoogle Scholar
• Skov BG, Holm B, Erreboe A, ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 2010;5:453-9
   PubMedGoogle Scholar
• Fasano M, Sabatini MT, Wieczorek R, CD44 and its v6 spliced variant in lung tumors: a role in histogenesis? Cancer 1997;80:34-41
   PubMedGoogle Scholar
• Granberg D, Wilander E, Oberg K, Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors. Int J Cancer 1999;84:484-88
   PubMedGoogle Scholar
• Erasmus JJ, McAdams HP, Patz EF Jr, Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369-73
   PubMed Web of Science ®Google Scholar
• Pasquali C, Rubello D, Sperti C, Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998;22:588-92
   PubMed Web of Science ®Google Scholar
• Traub T, Petkov V, Ofluoglu S, 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001;42:1309-15
   PubMedGoogle Scholar
• Hofmann M, Maecke H, Borner R, Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-7
   PubMedGoogle Scholar
• Belhocine T, Foidart J, Rigo P, Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 2002;23:727-34
   PubMedGoogle Scholar
• Zuetenhorst JM, Hoefnageli CA, Boot H, Evaluation of 111In-pentetreotide, 131I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735-41
   PubMedGoogle Scholar
• Tsagarakis S, Christoforaki M, Giannopoulou H, A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome. J Clin Endocrinol Metab 2003;88:4754-8
   PubMedGoogle Scholar
• Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93
   PubMed Web of Science ®Google Scholar
• Fanti S, Farsad M, Battista G, Somatostatin receptor scintigraphy for bronchial carcinoid follow-up. Clin Nucl Med 2003;28:548-52
   PubMedGoogle Scholar
• Granberg D, Sundin A, Janson ET, Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003;59:793-9
   PubMed Web of Science ®Google Scholar
• Wartski M, Alberini JL, Leroy-Ladurie F, Typical and atypical bronchopulmonary carcinoid tumors on FDG PET/CT imaging. Clin Nucl Med 2004;29:752-3
   PubMedGoogle Scholar
• Pacak K, Ilias I, Chen CC, The role of [18F]fluorodeoxyglucose positron emission tomography and [111In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 2004;89:2214-21
   PubMed Web of Science ®Google Scholar
• Plachcinska A, Mikolajczak R, Maecke H, Efficacy of 99mTc-EDDA/HYNIC-TOC scintigraphy in differential diagnosis of solitary pulmonary nodules. Cancer Biother Radiopharm 2004;19:613-20
   PubMedGoogle Scholar
• Orlefors H, Sundin A, Garske U, Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400
   PubMed Web of Science ®Google Scholar
• Yellin A, Zwas ST, Rozenman J, Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J 2005;7:712-16
   PubMed Web of Science ®Google Scholar
• Koopmans KP, de Vries EG, Kema IP, Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-34
   PubMedGoogle Scholar
• Kruger S, Buck AK, Blumstein NM, Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 2006;260:545-50
   PubMedGoogle Scholar
• Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-33
   PubMed Web of Science ®Google Scholar
• Volante M, Brizzi MP, Faggiano A, Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20:1172-82
   PubMed Web of Science ®Google Scholar
• Chong S, Lee KS, Kim BT, Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol 2007;188:1223-31
   PubMedGoogle Scholar
• Daniels CE, Lowe VJ, Aubry MC, The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007;131:255-60
   PubMed Web of Science ®Google Scholar
• Song YS, Lee WW, Chung JH, Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008;61:54-60
   PubMedGoogle Scholar
• Kayani I, Bomanji JB, Groves A, Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55
   PubMed Web of Science ®Google Scholar
• Korner MU, Hayes GM, Carrigan PE, Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue. Mod Pathol 2008;21:387-95
   PubMedGoogle Scholar
• Kayani I, Conry BG, Groves AM, A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-32
   PubMed Web of Science ®Google Scholar
• Miederer M, Seidl S, Buck A, Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48-52
   PubMed Web of Science ®Google Scholar
• Ambrosini V, Castellucci P, Rubello D, 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281-6
   PubMed Web of Science ®Google Scholar
• Kumar A, Jindal T, Dutta R, Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga DOTA-TOC PET-CT scan. Ann Nucl Med 2009;23:745-51
   PubMedGoogle Scholar
• Putzer D, Gabriel M, Henninger B, Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Cescato R, Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab 2010;95:2343-50
   PubMed Web of Science ®Google Scholar
• Binderup T, Knigge U, Loft A, Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51:704-12
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Kayani I, Quigley AM, The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875-82
   PubMed Web of Science ®Google Scholar
• Korner M, Eltschinger V, Waser B, Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005;29:1642-51
   PubMedGoogle Scholar
• Rodrigues M, Gabriel M, Heute D, Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1796-802
   PubMedGoogle Scholar
• Campana D, Ambrosini V, Pezzilli R, Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010;51:353-9
   PubMed Web of Science ®Google Scholar
• Garin E, Le Jeune F, Devillers A, Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 2009;50:858-64
   PubMed Web of Science ®Google Scholar
• Haug A, Auernhammer CJ, Wangler B, Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765-70
   PubMed Web of Science ®Google Scholar
• Gotthardt M, Behe MP, Grass J, Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006;13:1203-11
   PubMed Web of Science ®Google Scholar
• Reubi JC, Laderach U, Waser B, Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60:3105-12
   PubMed Web of Science ®Google Scholar
• Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377-86
   PubMed Web of Science ®Google Scholar
• Reubi JC, Wenger S, Schmuckli-Maurer J, Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR6, beta-ALA11, PHE13, NLE14] bombesin(6-14). Clin Cancer Res 2002;8:1139-46
   PubMed Web of Science ®Google Scholar
• Reubi JC, Kvols LK, Waser B, Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-77
   PubMed Web of Science ®Google Scholar
• Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging 2008;52:441-54
   PubMed Web of Science ®Google Scholar
• Virgolini IJ, Gabriel M, von Guggenberg E, Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours. Eur J Cancer 2009;45(Suppl 1):274-91
   PubMedGoogle Scholar
• Antunes P, Ginji M, Zhang H, Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93
   PubMed Web of Science ®Google Scholar
• Krenning E, Bakker W, Kwekkeboom D, Biodistribution of a new chelated somatostatin analogue, [In-111-DOTA-DPhe1- Tyr3]-octreotide; comparison with [111In-DTPA-D-Phe1]-octreotide in humans. J Nucl Med 1997;38:103
   PubMedGoogle Scholar
• Smith-Jones P, Bischof C, Leimer M, “MAURITIUS”: a novel tumour diagnostic and therapeutic somatostatin analogue. Endocrinology 1999;140:5136-48
   PubMed Web of Science ®Google Scholar
• Maina T, Nock B, Nikolopoulou A, [99mTc]demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med 2002;29:742-53
   Google Scholar
• De Jong M, Bernard B, De Bruin E, Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283-8
   PubMed Web of Science ®Google Scholar
• Wild D, Schmitt JS, Ginj M, DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47
   PubMed Web of Science ®Google Scholar
• Reyhan M, Aydin M, Yapar AF, Atypical carcinoid tumor detected incidentally on Tc-99m sestamibi myocardial perfusion scintigraphy. Clin Nucl Med 2004;29:129-31
   PubMedGoogle Scholar
• Yapar Z, Kibar M, Sukan A, Coincidental visualization of an atypical bronchial carcinoid on Tc-99m-sestamibi scan in Kallmann's syndrome. Ann Nucl Med 2002;16:61-5
   PubMedGoogle Scholar
• Isidori AM, Kaltsas G, Frajese V, Ocular metastases secondary to carcinoid tumors: the utility of imaging with [123I]meta-iodobenzylguanidine and [111In]DTPA pentetreotide. J Clin Endocrinol Metab 2002;87:1627-33
   PubMed Web of Science ®Google Scholar
• Rodriguez JA, Meyers MO, Jacome TH, Intraoperative detection of a bronchial carcinoid with a radiolabeled somatostatin analog. Chest 2002;121:985-8
   PubMedGoogle Scholar
• Grossrubatscher E, Vignati F, Dalino P, Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome. J Endocrinol Invest 2005;28:72-8
   PubMedGoogle Scholar
• Oberg K, Hellman P, Kwekkeboom D, Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v220-2
   Google Scholar
• Travis WD, Giroux DJ, Chansky K, The IASLC Lung Cancer Staging Project: proposals for the inclusion of bronchopulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for lung cancer. J Thorac Oncol 2008;3:1213-23
   PubMed Web of Science ®Google Scholar
• Druce MR, Lewington V, Grossman AB. Targeted radionuclide therapy for neuroendocrine tumours: principles and application. Neuroendocrinology 2010;91:1-15
   PubMed Web of Science ®Google Scholar
• Filosso PL, Ruffini E, Oliaro A, Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002;21:913-17
   PubMed Web of Science ®Google Scholar
• Hearn PR, Reynolds CL, Johansen K, Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin). Clin Endocrinol (Oxf) 1988;28:181-5
   PubMed Web of Science ®Google Scholar
• Lefebvre H, Jegou S, Leroux P, Characterization of the somatostatin receptor subtype in a bronchial carcinoid tumor responsible for Cushing's syndrome. J Clin Endocrinol Metab 1995;80:1423-8
   PubMedGoogle Scholar
• Melmed S, Ziel FH, Braunstein GD, Medical management of acromegaly due to ectopic production of growth hormone releasing hormone by a carcinoid tumor. J Clin Endocrinol Metab 1988;67:395-9
   PubMedGoogle Scholar
• Moller DE, Moses AC, Jones K, Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. J Clin Endocrinol Metab 1989;68:499-504
   PubMedGoogle Scholar
• Boizel R, Halimi S, Labat F, Acromegaly due to a growth hormone-releasing hormone-secreting bronchial carcinoid tumor: further information on the abnormal responsiveness of the somatotroph cells and their recovery after successful treatment. J Clin Endocrinol Metab 1987;64:304-8
   PubMedGoogle Scholar
• Fainstein Day P, Frohman L, Garcia Rivello H, Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary 2007;10:311-19
   PubMedGoogle Scholar
• Reith P, Monnot EA, Bathija PJ. Prolonged suppression of a corticotropin-producing bronchial carcinoid by oral bromocriptine. Arch Intern Med 1987;147:989-91
   PubMedGoogle Scholar
• Francia G, Davi MV, Montresor E, Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest 2006;29:358-62
   PubMedGoogle Scholar
• Granberg D, Eriksson B, Wilander E, Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-91
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327-34
   PubMedGoogle Scholar
• Guigay J, Ruffie P, Leboulleux S, Response of atypical pulmonary carcinoid tumors to chemotherapy. A retrospective study of 37 patients. J Thorac Oncol 2007;2(Suppl 4):S599
   Google Scholar
• Bajetta E, Ferrari L, Procopio G, Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002;13:614-21
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Procopio G, Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-42
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91
   PubMed Web of Science ®Google Scholar
• Waldherr C, Pless M, Maecke HR, The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5
   PubMed Web of Science ®Google Scholar
• Waldherr C, Pless M, Maecke HR, Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610-16
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Zoboli S, Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-16
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Grana C, Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038-46
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Bakker WH, Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007;34:1219-27
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Kam BL, Salvage therapy with 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2010;51:383-90
   PubMed Web of Science ®Google Scholar
• Seregni E, Maccauro M, Coliva A, Treatment with tandem [90Y]DOTA-TATE an [177Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging 2010;54:84-91
   PubMed Web of Science ®Google Scholar
• Schuller HM, Orloff M, Reznik GK. Antiproliferative effects of the Ca2+/calmodulin antagonist B859-35 and the Ca(2+)-channel blocker verapamil on human lung cancer cell lines. Carcinogenesis 1991;12:2301-3
   PubMedGoogle Scholar
• Marshall ME, Kervin K, Benefield C, Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro. J Cancer Res Clin Oncol 1994;120:S3-10
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Frederick LM, Ames MM. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000;6:4365-72
   PubMed Web of Science ®Google Scholar
• Goke R, Goke A, Goke B, Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion 2001;64:75-80
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Frederick LM, Pobst LJ, Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines. Biochem Pharmacol 2005;69:1159-66
   PubMedGoogle Scholar
• Van Gompel JJ, Kunnimalaiyaan M, Holen K, ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005;4:910-17
   PubMedGoogle Scholar
• Nakamura H, Takamori S, Fujii T, Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 2005;230:33-46
   PubMed Web of Science ®Google Scholar
• Mayburd AL, Martlinez A, Sackett D, Ingenuity network-assisted transcription profiling: identification of a new pharmacologic mechanism for MK886. Clin Cancer Res 2006;12:1820-7
   PubMed Web of Science ®Google Scholar
• Larsson DE, Lovborg H, Rickardson L, Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. Anticancer Res 2006;26:4125-9
   PubMedGoogle Scholar
• Yao JC, Zhang JX, Rashid A, Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-40
   PubMed Web of Science ®Google Scholar
• Ono K, Suzuki T, Miki Y, Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res 2007;27:2231-9
   PubMed Web of Science ®Google Scholar
• Greenblatt DY, Cayo M, Ning L, Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg 2007;11:1515-20
   PubMedGoogle Scholar
• Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007;12:942-51
   PubMed Web of Science ®Google Scholar
• Kunnimalaiyaan M, Ndiaye M, Chen H. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery 2007;142:959-64
   PubMedGoogle Scholar
• Mijatovic T, Roland I, Van Quaquebeke E, The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 2007;212:170-9
   PubMed Web of Science ®Google Scholar
• Sacewicz M, Lawnicka H, Siejka A, Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro. Cancer Lett 2008;268:120-8
   PubMed Web of Science ®Google Scholar
• Kidd M, Schally AV, Pfragner R, Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer 2008;112:1404-14
   PubMed Web of Science ®Google Scholar
• Kidd M, Drozdov I, Joseph R, Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008;113:690-700
   PubMed Web of Science ®Google Scholar
• Moreno A, Akcakanat A, Munsell MF, Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-66
   PubMed Web of Science ®Google Scholar
• Larsson DE, Hassan S, Larsson R, Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines. Cancer Chemother Pharmacol 2009;65:5-12
   PubMed Web of Science ®Google Scholar
• Adler JT, Hottinger DG, Kunnimalaiyaan M, Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol 2009;16:481-6
   PubMed Web of Science ®Google Scholar
• Drozdov I, Kidd M, Gustafsson BI, Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer 2009;115:4934-45
   PubMed Web of Science ®Google Scholar
• Pinchot SN, Adler JT, Luo Y, Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009;197:313-19
   Google Scholar
• Alexander VM, Roy M, Steffens KA, Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med 2010;3:95-102
   PubMedGoogle Scholar
• Chen JY, Cook MR, Pinchot SN, MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype. J Surg Res 2010;158:15-19
   PubMedGoogle Scholar
• Greenblatt DY, Ndiaye M, Chen H, Lithium inhibits carcinoid cell growth in vitro. Am J Transl Res 2010;2:248-53
   PubMedGoogle Scholar
• Larsson DE, Wickstrom M, Hassan S, The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. Anticancer Res 2010;30:149-56
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Minoia M, Martini C, Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010;17:719-29
   PubMed Web of Science ®Google Scholar
• Cakir M, Grossman AB. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opin Ther Targets 2009;13:1121-34
   PubMed Web of Science ®Google Scholar
• Zhang J, Jin W, Wang X, A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm 2010;7:1159-68
   PubMed Web of Science ®Google Scholar
• Lim E, Goldstraw P, Nicholson AG, Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2008;3:1194-201
   PubMed Web of Science ®Google Scholar